ArticleVeterinary world2025
A novel influenza vector-based vaccine expressing ESAT-6 and TB10.4 confers immunity and protection against
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Materials and Methods: Recombinant influenza A viruses expressing ESAT-6 and TB10.4 were constructed using reverse genetics and incorporated into vaccine formulations. Guinea pigs and calves were immunized with adjuvanted and non-adjuvanted formulations, followed by challenge with a virulent Results: Both formulations were safe and well-tolerated in guinea pigs and calves, with no adverse clinical signs. The non-adjuvanted vaccine induced the highest and most sustained IFNγ response, peaking between 2 and 5 months post-vaccination. In guinea pigs, the protection index reached +0.60 lg in the non-adjuvanted group versus +0.2 lg in the adjuvanted group. In calves, lung bacterial load was reduced to 1.83-1.93 lg colony-forming unit (CFU) in vaccinated animals compared with 5.8 lg CFU in unvaccinated controls. Histopathological examination confirmed minimal tissue damage in the vaccinated groups. Both vaccine formulations demonstrated protective efficacy equivalent to or better than BCG, with the non-adjuvanted version showing superior performance. Conclusion: This novel influenza vector-based vaccine expressing ESAT-6 and TB10.4 antigens elicits strong, long-lasting cellular immunity and provides significant protection against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.